A tale of two domains - a structural perspective of the pseudokinase, MLKL
Peter E Czabotar, James M Murphy
The FEBS Journal | WILEY | Published : 2015
Recently, the programmed necrosis or 'necroptosis' cell death pathway has attracted much interest because of its implication in multiple pathologies, including inflammatory diseases and the cell death arising from ischaemia reperfusion injuries. Pharmacologically, necroptosis is an attractive target because, unlike the counterpart pathway, apoptosis, it is dispensable for mammalian development. In particular, the most terminal-known obligate effector in the necroptosis pathway, the pseudokinase MLKL (mixed lineage kinase domain-like), holds particular appeal because, thus far, its only known function is as a mediator of necroptotic cell death. We review the current understanding and gaps in ..View full abstract
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by NHMRC IRIISS
The reviewed studies performed in the Czabotar and Murphy laboratories were supported by grants (637342, 1057905, 1067289) and a fellowship provided to PEC (1079700) from the National Health and Medical Research Council of Australia (NHMRC). PEC and JMM acknowledge support received from the Australian Research Council Future Fellowship Scheme. Additional support was provided by the Victorian State Government Operational Infrastructure Support and NHMRC IRIISS grant (9000220).